7/29/2016 | PP | Cardiome greenshoe exercised in $34.5 million public sale of stock
|
7/26/2016 | PP | Cardiome prices $30 million public offering of common stock at $3.00
|
7/25/2016 | PP | Cardiome Pharma announces plans to price public sale of common stock
|
1/12/2016 | PP | Cardiome may raise up to $20 million through equity purchase agreement
|
8/13/2015 | PP | Cardiome Pharma greenshoe exercised in $23 million public stock sale
|
7/29/2015 | PP | Cardiome Pharma increases its public offering of stock to $20 million
|
7/28/2015 | PP | Cardiome Pharma prices $15 million public offering of stock at $8.00
|
2/18/2014 | PP | Cardiome Pharma could raise $30 million from at-the-market offering
|
12/16/2010 | CVHYPF | Cardiome Pharma files $250 million shelf for stock, preferreds, debt
|
10/19/2009 | SS | Cardiome buys back nearly 10% of shares in Dutch auction tender offer
|
10/14/2009 | SS | Cardiome to buy shares for $4.25 each in Dutch auction tender offer
|
9/25/2009 | SS | Cardiome extends expiration of Dutch auction tender offer to Oct. 6
|
9/1/2009 | SS | Cardiome begins Dutch auction tender offer for up to 6,470,588 shares
|
8/25/2009 | SS | Cardiome Pharma to buy back up to 6.47 million shares in tender offer
|
10/27/2008 | SS | Unicredit reports 5% passive stake in Cardiome Pharma
|
10/23/2008 | CVHY | Cardiome files $250 million shelf registration
|
7/23/2008 | PP | Market Commentary: Cardiome sells $25 million; IGR wraps $1.3 million; Sheffield to get £14.29 million; Drury on tap
|
7/23/2008 | PP | New Issue: Cardiome negotiates $25 million convertible preferreds sale
|
10/10/2006 | BT | Cardiome files $150 million stock shelf
|
9/13/2006 | BT | Cardiome data show RSD1235 effective in lower dose
|
9/13/2006 | BT | Market Commentary: Vasogen zooms 24% on Celacade data; Cardiome off 11%; Oscient falls 11%, but fans buy on decline
|
9/12/2006 | BT | Cardiome preparing to resubmit application for RSD1235 in early Q4
|
7/24/2006 | BT | Cardiome says 300 mg oral RSD1235 well-tolerated in target population
|
7/10/2006 | BT | Cardiome: Astellas to fund new NDA filing for RSD1235
|
7/7/2006 | BT | Cardiome, development partner meet with FDA, to follow up on refusal-to-file letter for RSD1235
|
5/31/2006 | BT | Cardiome believes FDA's refusal of RSD1235 linked to presentation, not data
|
5/5/2006 | BT | Cardiome says oral RSD1235 safe, effective in trial
|
3/31/2006 | BT | Cardiome, Astellas file NDA for atrial fibrillation drug RSD1235
|
12/9/2005 | BT | Cardiome begins phase 2a study of RSD1235 for atrial fibrillation
|
10/19/2005 | BT | Cardiome, Astellas announce open-label study of atrial fibrillation drug
|
9/23/2005 | BT | Cardiome initiated by Rodman & Renshaw at market outperform
|
7/1/2005 | BT | Cardiome started by Leerink Swann at outperform
|